Arbutus Biopharma Corp

Arbutus Biopharma’s latest patent ruling sparks a high‑stakes legal battle with Moderna—explore how this impacts its hepatitis B drug pipeline and shaky finances.

Arbutus Biopharma Corporation is a biopharmaceutical company focused on developing treatments for chronic hepatitis B, with a pipeline of drug candidates and a market capitalization of approximately $686.28 million USD.

Arbutus Biopharma Corporation faces significant challenges and uncertainty in its financial performance and market positioning, raising questions about its growth prospects and ability to address chronic hepatitis B infection.